Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Deferasirox
Drug ID BADD_D00594
Description Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Indications and Usage For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Marketing Status Prescription
ATC Code V03AC03
DrugBank ID DB01609
KEGG ID D03669
MeSH ID D000077588
PubChem ID 214348
TTD Drug ID D0Q5UQ
NDC Product Code 62332-412; 43598-856; 57664-769; 62332-411; 62756-569; 0078-0469; 70771-1411; 66039-871; 69097-550; 70771-1471; 72647-371; 62512-0078; 68462-494; 69539-021; 31722-012; 69097-391; 57664-770; 58032-2017; 69539-200; 63278-1070; 72647-372; 46708-324; 69452-159; 62332-410; 53104-7713; 72606-014; 11722-040; 69097-570; 43598-851; 62332-324; 67877-549; 69539-022; 66022-0301; 0591-3853; 45963-456; 14501-0049; 46708-410; 62332-325; 46708-879; 72606-013; 62756-570; 69238-1486; 43598-854; 65085-0063; 62332-326; 69238-1704; 70710-1011; 59285-010; 46708-326; 70710-1012; 59651-419; 16714-995; 69539-199; 72205-076; 65727-037; 74436-0323; 57664-768; 68462-495; 46708-325; 69452-160; 0078-0713; 65015-738; 16714-993; 69097-393; 69097-560; 0078-0470; 31722-013; 69539-074; 43598-853; 70700-269; 70771-1409; 49706-2103; 70710-1277; 43598-855; 0078-0468; 65372-1164; 16714-994; 43598-852; 45963-455; 46708-412; 0078-0727; 70771-1472; 72647-373; 68462-496; 67877-553; 69238-1703; 45963-454; 69452-161; 0078-0654; 62756-568; 70771-1473; 69539-023; 67877-550; 0078-0720; 70710-1275; 31722-011; 72606-015; 70771-1410; 69539-075; 67877-551; 70710-1013; 67877-554; 72205-075; 0078-0656; 70700-270; 69238-1702; 0078-0655; 46708-411; 69097-392; 69539-073; 69238-1487; 67877-552; 70700-271; 70710-1276; 69238-1488
Synonyms Deferasirox | 4-(3,5-Bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid | ICL 670A | ICL-670A | ICL670A | ICL-670 | ICL670 | ICL 670 | Exjade
Chemical Information
Molecular Formula C21H15N3O4
CAS Registry Number 201530-41-8
SMILES C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eosinophil count increased13.01.06.0040.008747%Not Available
Eosinophilia01.02.04.001--
Epilepsy17.12.03.0020.026240%Not Available
Epistaxis24.07.01.005; 22.04.03.0010.058312%
Epstein-Barr virus infection11.05.10.0040.005831%
Erysipelas11.02.06.001; 23.09.01.0020.005831%Not Available
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.0150.014578%
Eye disorder06.08.03.001--Not Available
Eye haemorrhage24.07.05.002; 06.07.02.0010.005831%Not Available
Eye irritation06.04.05.003--Not Available
Eye pain06.08.03.002--
Eye swelling06.08.03.003--Not Available
Face oedema23.04.01.004; 08.01.07.003; 10.01.05.002--
Faeces discoloured07.01.03.0020.069974%Not Available
Faeces hard07.01.03.0030.005831%Not Available
Failure to thrive18.04.01.003; 14.03.02.008; 19.07.05.0010.002282%Not Available
Fanconi syndrome20.05.03.009; 14.01.01.011; 03.06.01.0010.026240%Not Available
Fatigue08.01.01.002--
Febrile neutropenia08.05.02.004; 01.02.03.0020.034987%
Feeling abnormal08.01.09.014--Not Available
Feeling hot08.01.09.009--Not Available
Femur fracture15.08.03.003; 12.04.01.003--Not Available
Flank pain20.02.03.006; 15.03.04.003; 08.01.08.0070.017494%
Flatulence07.01.04.002--
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Foot fracture15.08.03.012; 12.04.01.012--Not Available
Fracture15.08.02.001; 12.04.02.0010.026240%
Frequent bowel movements07.02.04.0020.014578%Not Available
Fungal infection11.03.05.001--Not Available
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 28 Pages